title: MiRNAs-mediated cisplatin resistance in breast cancer.
abstract: Cisplatin is a widely used chemotherapeutic agent in breast cancer treatments with inevitable rapidly acquired resistance or intrinsically resistance. Enormous evidence points to the bioprocesses of resistant formation consisting of diverse miRNAs direct and indirect actions on relevant encoding genes. In this report, we overview detailed information on the miRNAs effect on cisplatin-induced resistance, including alterations in cell survival, modification of DNA damage response, changes in cellular uptake or efflux of the drug, altered DNA methylation, and perturbations in the miRNA biogenesis pathway. This will provide potential miRNA-targeted strategies for the treatment of breast cancer therapy and requires further clinical application.
authors.affiliation: The Fourth Clinical School of Nanjing Medical University, Baiziting42, Nanjing, China.|Department of General Surgery, Jiangsu Cancer Hospital Affiliated to Nanjing Medical University and First Affiliated Hospital of Nanjing Medical University, 210009, Baiziting42, Nanjing, China.
authors.forename: Xiu
authors.initials: X
authors.lastname: Chen
authors.affiliation: School of Public Health Nanjing Medical University, Longmiandadao101, Nanjing, China.
authors.forename: Peng
authors.initials: P
authors.lastname: Lu
authors.affiliation: The First Clinical School of Nanjing Medical University, Baiziting42, Nanjing, China.
authors.forename: Ying
authors.initials: Y
authors.lastname: Wu
authors.affiliation: Department of General Surgery, Jiangsu Cancer Hospital Affiliated to Nanjing Medical University and First Affiliated Hospital of Nanjing Medical University, 210009, Baiziting42, Nanjing, China.
authors.forename: Dan-Dan
authors.initials: DD
authors.lastname: Wang
authors.affiliation: Department of General Surgery, Jiangsu Cancer Hospital Affiliated to Nanjing Medical University and First Affiliated Hospital of Nanjing Medical University, 210009, Baiziting42, Nanjing, China.
authors.forename: Siying
authors.initials: S
authors.lastname: Zhou
authors.affiliation: The Fourth Clinical School of Nanjing Medical University, Baiziting42, Nanjing, China.|Department of General Surgery, Jiangsu Cancer Hospital Affiliated to Nanjing Medical University and First Affiliated Hospital of Nanjing Medical University, 210009, Baiziting42, Nanjing, China.
authors.forename: Su-Jin
authors.initials: SJ
authors.lastname: Yang
authors.affiliation: The Fourth Clinical School of Nanjing Medical University, Baiziting42, Nanjing, China.|Department of General Surgery, Jiangsu Cancer Hospital Affiliated to Nanjing Medical University and First Affiliated Hospital of Nanjing Medical University, 210009, Baiziting42, Nanjing, China.
authors.forename: Hong-Yu
authors.initials: HY
authors.lastname: Shen
authors.affiliation: Center of Clinical Laboratory Science, Jiangsu Cancer Hospital Affiliated to Nanjing Medical University, Baiziting42, Nanjing, China.
authors.forename: Xiao-Hui
authors.initials: XH
authors.lastname: Zhang
authors.affiliation: Center of Clinical Laboratory Science, Jiangsu Cancer Hospital Affiliated to Nanjing Medical University, Baiziting42, Nanjing, China.
authors.forename: Jian-Hua
authors.initials: JH
authors.lastname: Zhao
authors.affiliation: Department of General Surgery, Jiangsu Cancer Hospital Affiliated to Nanjing Medical University and First Affiliated Hospital of Nanjing Medical University, 210009, Baiziting42, Nanjing, China. jschjhtang@163.com.
authors.forename: Jin-Hai
authors.initials: JH
authors.lastname: Tang
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D001943:Breast Neoplasms / Q000188:drug therapy / Q000235:genetics*; D002945:Cisplatin / Q000494:pharmacology*; D019008:Drug Resistance, Neoplasm / Q000235:genetics*; D005260:Female; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects*; D006801:Humans; D035683:MicroRNAs / Q000235:genetics*
chemical_list: D000970:Antineoplastic Agents; D035683:MicroRNAs; D002945:Cisplatin
keywords: Breast; Cisplatin; Drug resistance; miRNAs